Search

Your search keyword '"Morabito, Fortunato"' showing total 243 results
Start Over Author "Morabito, Fortunato" Publication Year Range Last 3 years
243 results on '"Morabito, Fortunato"'

1. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, Riccardo, Rossi, Francesca Maria, Vit, Filippo, Bittolo, Tamara, Zucchetto, Antonella, Papotti, Robel, Tissino, Erika, Pozzo, Federico, Degan, Massimo, Polesel, Jerry, Bulian, Pietro, Marasca, Roberto, Reda, Gianluigi, Laurenti, Luca, Olivieri, Jacopo, Chiarenza, Annalisa, Laureana, Roberta, Postorino, Massimiliano, Del Principe, Maria Ilaria, Cuneo, Antonio, Gentile, Massimo, Morabito, Fortunato, Fronza, Gilberto, Tafuri, Agostino, Zaja, Francesco, Foà, Robin, Di Raimondo, Francesco, Del Poeta, Giovanni, and Gattei, Valter

Published
2023
Full Text
View/download PDF

2. Outcomes Before and After Implementation of the ERAS (Enhanced Recovery After Surgery) Protocol in Open and Laparoscopic Colorectal Surgery: A Comparative Real-World Study from Northern Italy

Author

Mangone, Lucia, primary, Mereu, Federica, additional, Zizzo, Maurizio, additional, Morini, Andrea, additional, Zanelli, Magda, additional, Marinelli, Francesco, additional, Bisceglia, Isabella, additional, Braghiroli, Maria Barbara, additional, Morabito, Fortunato, additional, Neri, Antonino, additional, and Fabozzi, Massimiliano, additional

Published
2024
Full Text
View/download PDF

3. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Stanzione, Gaia, additional, Zimbo, Annamaria, additional, Lugli, Elisabetta, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

4. MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

Author

Matis, Serena, Grazia Recchia, Anna, Colombo, Monica, Cardillo, Martina, Fabbi, Marina, Todoerti, Katia, Bossio, Sabrina, Fabris, Sonia, Cancila, Valeria, Massara, Rosanna, Reverberi, Daniele, Emionite, Laura, Cilli, Michele, Cerruti, Giannamaria, Salvi, Sandra, Bet, Paola, Pigozzi, Simona, Fiocca, Roberto, Ibatici, Adalberto, Angelucci, Emanuele, Gentile, Massimo, Monti, Paola, Menichini, Paola, Fronza, Gilberto, Torricelli, Federica, Ciarrocchi, Alessia, Neri, Antonino, Fais, Franco, Tripodo, Claudio, Morabito, Fortunato, Ferrarini, Manlio, and Cutrona, Giovanna

Published
2022
Full Text
View/download PDF

5. Momelotinib in myelofibrosis

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Fragliasso, Valentina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

6. Selinexor in multiple myeloma

Author

Martino, Enrica Antonia, primary, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Zimbo, Annamaria, additional, Torricelli, Federica, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

7. Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Stanzione, Gaia, Zimbo, Annamaria, Pozzi, Stefano, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Abstract

ABSTRACTIntroductionCXCR4/CXCL12 axis regulates cell proliferation, survival, and differentiation, as well as the homing and mobilization of hematopoietic stem cells (HSCs) from bone marrow niches to the peripheral blood. Furthermore, CXCR4 and CXCL12 are key mediators of cross-talk between hematological malignancies and their microenvironments. CXCR4 overexpression drives disease progression, boosts tumor cell survival, and promotes chemoresistance, leading to poor prognosis.Areas coveredIn light of these discoveries, scientific investigations, and clinical trials have underscored the therapeutic promise found in small-molecule antagonists like plerixafor, peptides/peptidomimetics, such as BKT140, monoclonal antibodies like PF-06747143 and ulocuplumab, as well as microRNAs. Their efficacy is evident in reducing tumor burden, inducing apoptosis and sensitizing malignant cells to conventional chemotherapies. This overview delves into the pathogenic role of the CXC4/CXCL12 axis in hematological neoplasms and examines the clinical application of key CXCR4 antagonists.Expert opinionThe information collectively emphasizes the potential of CXCR4 antagonists as a therapeutic strategy for hematologic malignancies, showcasing advancements in preclinical and clinical studies. As these therapeutic strategies progress through clinical trials, their potential to reshape the prognosis of hematologic malignancies will become increasingly apparent.

Published
2024
Full Text
View/download PDF

9. Malignant Mesothelioma Patterns in Emilia-Romagna: A Retrospective Asbestos Exposure Assessment (1996-2023).

Author

GIACOMINO, FAUSTO, MARINELLI, FRANCESCO, BISCEGLIA, ISABELLA, CACCHI, MARCO, STORCHI, CINZIA, PINTO, CARMINE, MORABITO, FORTUNATO, MANGONE, LUCIA, and ROMANELLI, ANTONIO

Abstract

Background: Malignant mesothelioma (MM) is a rare but lethal cancer strongly associated with asbestos exposure. This retrospective study examines mesothelioma trends and past asbestos exposure assessment in Emilia-Romagna, Northern Italy. Methods: Between 1996 and 2023, 3,513 cases of MM were recorded by the Regional Operating Center, predominantly in males (72%) and older than 65 years (79%). MM diagnosis was defined as certain, probable, and possible. Information concerning asbestos exposure was collected through an analytical questionnaire administered to patients or proxies and classified as occupational and non-occupational. Results: Occupational exposure accounted for 82% of cases, significantly increasing from 71% to 88% in the most recent period. A more accurate definition of occupational exposure indicates that specific exposure has gone from 49% in the first period to 62% and 58% in the last two periods; probable exposure decreased from 21% to 16%, while possible exposure decreased from 16% to 13%. Familiar exposure remained relatively constant at around 8%, environmental exposure slightly decreased from 4% to 2%, while non-occupational exposure remained stable at 2%. Among patients with exclusively occupational exposure (1,826 cases), 87% were male and aged between 65 and 75 years (36%) and 75+ (41%). Exposure rates for the province of residence see the province of Reggio Emilia with the highest occupational exposure rate (2.5 x 100,000 residents), followed by Ravenna (2.3 x 100,000 residents) and Parma and Piacenza, which have similar exposure rates with 2.2 x 100,000 residents. Occupational sectors such as construction, railway maintenance, and metalworking are identified as high-risk industries. Despite efforts to mitigate exposure, non-occupational and environmental exposures persist. The study highlights the importance of continuous surveillance and exposure monitoring to guide effective interventions and legal recognition of MM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Characteristics and Outcomes of Colorectal Cancer Patients Cared for by the Multidisciplinary Team in the Reggio Emilia Province, Italy.

Author

Mangone, Lucia, Marinelli, Francesco, Bisceglia, Isabella, Braghiroli, Maria Barbara, Banzi, Maria, Damato, Angela, Iori, Veronica, Pinto, Carmine, Cerullo, Loredana, Pellegri, Carlotta, Zizzo, Maurizio, Morabito, Fortunato, Neri, Antonino, and Giorgi Rossi, Paolo

Subjects
RISK assessment, CANCER relapse, RESEARCH funding, SURVIVAL rate, CANCER patient medical care, MULTIPLE regression analysis, COLORECTAL cancer, AGE distribution, REPORTING of diseases, DESCRIPTIVE statistics, MULTIVARIATE analysis, STATISTICS, RESEARCH methodology, TUMOR classification, SURVIVAL analysis (Biometry), COMPARATIVE studies, CONFIDENCE intervals, PROGRESSION-free survival, HEALTH care teams, PROPORTIONAL hazards models
Abstract

Simple Summary: Colorectal cancer remains a prevalent neoplasm affecting both genders. Despite advancements in screening techniques facilitating early detection, effective patient management remains paramount. This study investigates the impact of a multidisciplinary team (MDT) approach on patient outcomes. Results reveal a significant improvement in survival rates among MDT-followed patients compared to those lacking MDT oversight. Notably, no-MDT patients exhibited a twofold increase in mortality risk from both colon and rectal cancers. Furthermore, advanced age (>70 years) and advanced-stage disease (III and IV) emerged as pivotal risk factors. Consequently, prioritizing MDT intervention for these high-risk cohorts is imperative to optimize therapeutic strategies. Colorectal cancer emerged as the third most prevalent malignancy worldwide, affecting nearly 2 million individuals in the year 2020. This study elucidates the pivotal role of a multidisciplinary team (MDT) in influencing the prognosis, as measured by relative survival rates, depending upon the stage and age. Cases recorded in an Italian Cancer Registry between 2017 and 2018 were included. Relative survival was reported at 1 and 3 years after diagnosis comparing MDT vs. no-MDT approaches. During the study period, 605 CRCs were recorded while 361 (59.7%) were taken care of by an MDT. Compared to no-MDT, MDT patients were younger with earlier stages and received more surgery. One year after diagnosis, survival was 78.7% (90% in MDT vs. 62% in no-MDT); stratifying by stage, in the MDT group there was no survival advantage for stage I (97.2% vs. 89.9%) and II (96.8% vs. 89.4%), but an advantage was observed for stage III (86.4% vs. 56.9%) and stage IV (63.7% vs. 27.4%). Similar values were observed at 3 years where a marked advantage was observed for stages III (69.9% vs. 35.1%) and IV (29.2% vs. 5.1%). The univariable analysis confirmed an excess risk in the no-MDT group (HR 2.6; 95% CI 2.0–3.3), also confirmed in the multivariable regression analysis (HR 2.0; 95% CI 1.5–2.5). Despite the increase in the number of MDT patients in 2018 (from 50% to 69%), this does not correspond to an improvement in outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern Italy.

Author

Mangone, Lucia, Marinelli, Francesco, Bisceglia, Isabella, Filice, Angelina, Braghiroli, Maria Barbara, Roncaglia, Francesca, Palicelli, Andrea, Morabito, Fortunato, Neri, Antonino, Sabbatini, Roberto, Iotti, Cinzia, and Pinto, Carmine

Subjects
MEDICAL care, CANCER diagnosis, DELAYED diagnosis, COVID-19 pandemic, PROSTATE cancer, COVID-19
Abstract

Simple Summary: COVID-19 has had a dramatic impact on new cancer diagnoses and the treatment of cancer patients. This study examines how the COVID-19 pandemic affected prostate cancer diagnosis, staging, and treatment in Reggio Emilia, Northern Italy. Using data from the Cancer Registry from 2018 to 2021, we found a significant drop in new prostate cancer diagnoses during 2020, the height of the pandemic. The number of new cases decreased by 31% in 2020, with a slight recovery of 5% in 2021. We also observed a shift towards more advanced stages and aggressive forms of prostate cancer, with fewer early-stage diagnoses and more cases of metastatic cancer. Despite these changes, treatments such as surgery and radiation therapy have remained constant. The pandemic disrupted an increasing trend of prostate cancer diagnoses seen before 2019, highlighting the need for ongoing diagnostic services and healthcare delivery, even during global health emergencies. Our study highlights the significant impact of COVID-19 on prostate cancer management and the importance of healthcare system resilience. The COVID-19 pandemic has caused delays in cancer diagnoses and reductions in treatments. The aim of this work is to evaluate the impact of the pandemic on prostate cancer by evaluating whether there has been a shift towards more aggressive (Gleason) and more advanced tumors (stage IV) and a decline in treatments. The study was conducted on 1123 cases of prostate cancer incident in the Province of Reggio Emilia, Northern Italy, in the period of 2018–2021. In 2020, there was a decline in new diagnoses of prostate cancer (−31%), followed by a slight recovery in 2021 (+5%). While Gleason 7 and 8–10 values remained constant, a significant decrease was recorded in stage I (38.7%, 41.6%, 35.5%, and 27.7%) and an increase in stage IV (13.1%, 13%, 15.4%, and 20%) cases in the years 2018, 2019, 2020, and 2021, respectively. However, there was no impact on surgical treatment (which remained constant at around 35%) and radiotherapy (around 39%). Our findings underline the profound impact of COVID-19 on prostate cancer management, highlighting the importance of healthcare resilience in the face of unprecedented disruptions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Capodanno, Isabella, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
MYELODYSPLASTIC syndromes, ACUTE leukemia, NATURAL immunity, BONE marrow, LENALIDOMIDE, MYELOFIBROSIS
Abstract

Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with del(5q) being the most prevalent. Since its first description, del(5q) was consistently correlated with a typical clinical phenotype marked by anemia, thrombocytosis, and a low risk of evolving into acute leukemia. Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as "myelodysplastic neoplasm with low blast and isolated del(5q)" identified by the sole presence of 5q deletion or in combination with one other abnormality excluding −7/del(7q). Several studies have sought to unravel the biological processes triggered by del(5q) in the development of MDS, revealing the involvement of various genes localized in specific regions of chromosome 5 referred to as common deleted regions (CDR). This intricate biological landscape makes the MDS cells with del(5q) exceptionally sensitive to lenalidomide. Several studies have confirmed the efficacy of lenalidomide in this context. Regrettably, the response to lenalidomide is not conclusive, prompting ongoing research into biological mechanisms that drive patients toward leukemia and strategies to circumvent lenalidomide resistance and disease progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

14. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Author

Martino, Enrica Antonia, primary, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Laurenti, Luca, additional, Visentin, Andrea, additional, Frustaci, Annamaria, additional, Vigna, Ernesto, additional, Pepe, Sara, additional, Catania, Gioacchino, additional, Loseto, Giacomo, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Sportoletti, Paolo, additional, Del Principe, Maria Ilaria, additional, Laureana, Roberta, additional, Coscia, Marta, additional, Galimberti, Sara, additional, Ferretti, Eleonora, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Polesel, Jerry, additional, Tedeschi, Alessandra, additional, Rossi, Davide, additional, Trentin, Livio, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2024
Full Text
View/download PDF

18. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature

Author

Barbieri, Emiliano, Martino, Enrica Antonia, Rivolti, Elena, Quaresima, Micol, Vigna, Ernesto, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Abstract

ABSTRACTIntroductionGain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclonal antibodies (moAbs) implicated + 1q in poor prognoses, prompting its integration into novel staging systems. However, with the emergence of daratumumab and isatuximab, two pivotal anti-CD38 moAbs, the landscape of MM therapy has undergone a profound transformation.Areas coveredThis review encompasses a comprehensive analysis of diverse study methodologies, including observational investigations, clinical trials, meta-analyses, and real-world database analyses. By synthesizing these data sources, we aim to provide an overview of the current understanding of + 1q in the context of anti-CD38 moAbs therapies.Expert opinionDespite the paucity of available data, evidence suggests a potential mitigating effect of daratumumab on the adverse prognostic implications of + 1q. However, this benefit seems to diminish in patients harboring ≥ 4 copies or with concurrent high-risk CAs. On the other hand, isatuximab demonstrated promising outcomes in the relapsed-refractory setting for + 1q MM patients. Nevertheless, direct comparison between the two compounds is currently challenging. The current evidence firmly supports the integration of anti-CD38 moAb-based therapies as the standard of care for + 1q patients, pending further elucidation.

Published
2024
Full Text
View/download PDF

19. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

20. Teclistamab‐cqyv in multiple myeloma.

Author

Martino, Enrica Antonia, Bruzzese, Antonella, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
MULTIPLE myeloma, BISPECIFIC antibodies, PLASMA cells, PATIENT experience, DISEASE relapse, PLASMACYTOMA
Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and mortality. Despite advances in treatment, MM patients eventually experienced a relapse of the disease. Penta‐drug refractory patients continue to be the hard core of relapsed/refractory (RR) settings. Teclistamab‐cqyv is a humanized IgG4 antibody and a bispecific BCMA‐director CD3 T‐cell engager. It recruits endogenous T cells, by targeting CD3 receptors expressed on their surface, resulting in their activation against BCMA, an antigen expressed by plasma cells. US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Teclistamab‐cqyv in monotherapy for the treatment of RRMM patients who have received at least three prior therapies, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti‐CD38 monoclonal antibodies (MoAbs) and have demonstrated disease progression during the last therapy. Its effectiveness was demonstrated in a pivotal clinical trial where the overall response rate (ORR) reached 60%. Other clinical studies are currently ongoing to investigate the association of the bispecific antibody with novel drugs with encouraging preliminary results, especially in the setting of heavily pretreated patients. In this review, the authors will provide a comprehensive overview of the drug, including its mechanism of action, major clinical trials, and future perspectives. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Ivosidenib in acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Labanca, Caterina, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

22. Teclistamab‐cqyv in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

23. Tagraxofusp in myeloid malignancies

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Imovilli, Annalisa, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

24. Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy

Author

Morabito, Fortunato, primary, Adornetto, Carlo, additional, Monti, Paola, additional, Amaro, Adriana, additional, Reggiani, Francesco, additional, Colombo, Monica, additional, Rodriguez-Aldana, Yissel, additional, Tripepi, Giovanni, additional, D’Arrigo, Graziella, additional, Vener, Claudia, additional, Torricelli, Federica, additional, Rossi, Teresa, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Cutrona, Giovanna, additional, Gentile, Massimo, additional, and Greco, Gianluigi, additional

Published
2023
Full Text
View/download PDF

25. Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura

Author

Bruzzese, Antonella, primary, Vigna, Ernesto, additional, Terzi, Dario, additional, Greco, Sonia, additional, Martino, Enrica Antonia, additional, Vangeli, Valeria, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Labanca, Caterina, additional, Morelli, Rosellina, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Zinno, Francesco, additional, Mastroianni, Antonio, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

26. Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020

Author

Mangone, Lucia, primary, Penna, Domenico, additional, Marinelli, Francesco, additional, Roncaglia, Francesca, additional, Bisceglia, Isabella, additional, Merli, Francesco, additional, Ruffini, Alessia, additional, Gamberi, Barbara, additional, Tieghi, Alessia, additional, Valli, Riccardo, additional, Albertazzi, Laura, additional, Iori, Mauro, additional, Giorgi Rossi, Paolo, additional, Vener, Claudia, additional, Morabito, Fortunato, additional, Neri, Antonino, additional, and Luminari, Stefano, additional

Published
2023
Full Text
View/download PDF

27. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials

Author

Gentile, Massimo, primary, Vigna, Ernesto, additional, Palmieri, Salvatore, additional, Galli, Monica, additional, Derudas, Daniele, additional, Mina, Roberto, additional, Pepa, Roberta Della, additional, Zambello, Renato, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mangiacavalli, Silvia, additional, Zamagni, Elena, additional, Califano, Catello, additional, Musso, Maurizio, additional, Conticello, Concetta, additional, Cerchione, Claudio, additional, Mele, Giuseppe, additional, Di Renzo, Nicola, additional, Offidani, Massimo, additional, Tarantini, Giuseppe, additional, Casaluci, Gloria Margiotta, additional, Rago, Angela, additional, Ria, Roberto, additional, Uccello, Giuseppina, additional, Barilà, Gregorio, additional, Palumbo, Gaetano, additional, Pompa, Alessandra, additional, Vincelli, Donatella, additional, Brunori, Marino, additional, Accardi, Fabrizio, additional, Amico, Valeria, additional, Amendola, Angela, additional, Fontana, Raffaele, additional, Bongarzoni, Velia, additional, Rossini, Bernardo, additional, Cotzia, Emilia, additional, Gozzetti, Alessandro, additional, Rizzi, Rita, additional, Sgherza, Nicola, additional, Ferretti, Eleonora, additional, Bertuglia, Giuseppe, additional, Nappi, Davide, additional, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Musto, Pellegrino, additional

Published
2023
Full Text
View/download PDF

28. Glasdegib for the treatment of acute myeloid leukemia

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Fimognari, Filippo, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

29. Zanubrutinib for the treatment of chronic lymphocytic leukemia

Author

Bruzzese, Antonella, primary, Martino, Enrica Antonia, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

30. Belantamab mafodotin in multiple myeloma

Author

Martino, Enrica Antonia, primary, Bruzzese, Antonella, additional, Iaccino, Enrico, additional, Labanca, Caterina, additional, Mendicino, Francesco, additional, Mimmi, Selena, additional, Lucia, Eugenio, additional, Olivito, Virginia, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, Vigna, Ernesto, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

31. Tagraxofusp in myeloid malignancies.

Author

Bruzzese, Antonella, Martino, Enrica Antonia, Labanca, Caterina, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Imovilli, Annalisa, Morabito, Fortunato, Vigna, Ernesto, and Gentile, Massimo

Subjects
DIPHTHERIA toxin, RECOMBINANT molecules, INTERLEUKIN-3, ADP-ribosylation, DENDRITIC cells
Abstract

Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp‐azacytidine‐venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123‐positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123‐positive myeloid malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Optimizing Outcomes through a Multidisciplinary Team Approach in Endometrial Cancer.

Author

Mangone, Lucia, Marinelli, Francesco, Bisceglia, Isabella, Braghiroli, Maria Barbara, Mastrofilippo, Valentina, Pezzarossi, Annamaria, Morabito, Fortunato, Aguzzoli, Lorenzo, and Mandato, Vincenzo Dario

Subjects
EVALUATION of medical care, ADJUVANT chemotherapy, SCIENTIFIC observation, CONFIDENCE intervals, MULTIVARIATE analysis, CANCER relapse, RETROSPECTIVE studies, REGRESSION analysis, ENDOMETRIAL tumors, HEALTH care teams, KAPLAN-Meier estimator, DESCRIPTIVE statistics, RESEARCH funding, PROGRESSION-free survival, DATA analysis software, OVERALL survival, PROPORTIONAL hazards models
Abstract

This study aimed to assess the impact of a multidisciplinary team (MDT) approach on outcomes with endometrial cancer (EC) patients, utilizing 2013–2020 data from the Reggio Emilia Cancer Registry. Recurrence rate, treatments, and outcome indicators were compared between the MDT (319 cases) and non-MDT (324 cases) groups. Among 643 cases, 52.4% were over 65 years old, 98% had microscopic confirmation, and 73% were in stage I. Surgery was performed in 89%, with 41% receiving adjuvant therapies. Recurrence rates (10%) were similar between the two groups, but MDT patients who were older and predominantly in stage I exhibited 79% recurrence within one year (21% in the non-MDT group). Disease-free survival (DFS) showed no significant difference [HR 1.1; 95% CI 0.7–1.6], while differences in overall survival (OS) were notable [HR 1.5; 95% CI 1.0–2.4]. The 5-year OS rates were 87% and 79% in the MDT and non-MDT groups. Comparing the 2013–2015 to 2016–2020 study periods, a shift towards caring for older women, more advanced-stage patients, and those residing outside the metropolitan area, along with a greater number of relapsed cases (from 16% to 76%), were accounted for. These findings underscore the impact of an MDT on EC outcomes, highlighting the evolving patient demographics over time. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Mauro, Francesca Romana, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Moia, Riccardo, additional, Condoluci, Adalgisa, additional, Vincelli, Iolanda, additional, Chiarenza, Annalisa, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mezzatesta, Sabrina, additional, Laureana, Roberta, additional, Cutrona, Giovanna, additional, Di Raimondo, Francesco, additional, Fronza, Gilberto, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Rossi, Francesca Maria, additional, Olivieri, Jacopo, additional, Zaja, Francesco, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Del Principe, Maria Ilaria, additional, Ilariucci, Fiorella, additional, Del Poeta, Giovanni, additional, Ferrarini, Manlio, additional, Neri, Antonino, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2023
Full Text
View/download PDF

34. Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion

Author

Mosca, Laura, primary, Fabris, Sonia, primary, Lionetti, Marta, primary, Todoerti, Katia, primary, Agnelli, Luca, primary, Morabito, Fortunato, primary, Cutrona, Giovanna, primary, Andronache, Adrian, primary, Matis, Serena, primary, Ferrari, Francesco, primary, Gentile, Massimo, primary, Spriano, Mauro, primary, Callea, Vincenzo, primary, Festini, Gianluca, primary, Molica, Stefano, primary, Deliliers, Giorgio Lambertenghi, primary, Bicciato, Silvio, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

Author

Lionetti, Marta, primary, Musto, Pellegrino, primary, Di Martino, Maria Teresa, primary, Fabris, Sonia, primary, Agnelli, Luca, primary, Todoerti, Katia, primary, Tuana, Giacomo, primary, Mosca, Laura, primary, Gallo Cantafio, Maria E., primary, Grieco, Vitina, primary, Bianchino, Gabriella, primary, D'Auria, Fiorella, primary, Statuto, Teodora, primary, Mazzoccoli, Carmela, primary, De Luca, Luciana, primary, Petrucci, Maria Teresa, primary, Offidani, Massimo, primary, Di Raimondo, Francesco, primary, Falcone, Antonietta, primary, Caravita, Tommaso, primary, Omede', Paola, primary, Morabito, Fortunato, primary, Tassone, Pierfrancesco, primary, Boccadoro, Mario, primary, Palumbo, Antonio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Author

Vigneri, Paolo, primary, Stagno, Fabio, primary, Stella, Stefania, primary, Cupri, Alessandra, primary, Forte, Stefano, primary, Massimino, Michele, primary, Antolino, Agostino, primary, Siragusa, Sergio, primary, Mannina, Donato, primary, Impera, Stefana Stella, primary, Musolino, Caterina, primary, Malato, Alessandra, primary, Mineo, Giuseppe, primary, Tomaselli, Carmela, primary, Murgano, Pamela, primary, Musso, Maurizio, primary, Morabito, Fortunato, primary, Molica, Stefano, primary, Martino, Bruno, primary, Manzella, Livia, primary, Müller, Martin C., primary, Hochhaus, Andreas, primary, and Raimondo, Francesco Di, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

Author

Todoerti, Katia, primary, Agnelli, Luca, primary, Fabris, Sonia, primary, Lionetti, Marta, primary, Tuana, Giacomo, primary, Mosca, Laura, primary, Lombardi, Luigia, primary, Grieco, Vitina, primary, Bianchino, Gabriella, primary, D'Auria, Fiorella, primary, Statuto, Teodora, primary, Mazzoccoli, Carmela, primary, De Luca, Luciana, primary, Petrucci, Maria Teresa, primary, Morabito, Fortunato, primary, Offidani, Massimo, primary, Di Raimondo, Francesco, primary, Falcone, Antonietta, primary, Omede', Paola, primary, Tassone, Pierfrancesco, primary, Boccadoro, Mario, primary, Palumbo, Antonio, primary, Neri, Antonino, primary, and Musto, Pellegrino, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome

Author

Todoerti, Katia, primary, Agnelli, Luca, primary, Fabris, Sonia, primary, Lionetti, Marta, primary, Tuana, Giacomo, primary, Mosca, Laura, primary, Lombardi, Luigia, primary, Grieco, Vitina, primary, Bianchino, Gabriella, primary, D'Auria, Fiorella, primary, Statuto, Teodora, primary, Mazzoccoli, Carmela, primary, De Luca, Luciana, primary, Petrucci, Maria Teresa, primary, Morabito, Fortunato, primary, Offidani, Massimo, primary, Di Raimondo, Francesco, primary, Falcone, Antonietta, primary, Omede', Paola, primary, Tassone, Pierfrancesco, primary, Boccadoro, Mario, primary, Palumbo, Antonio, primary, Neri, Antonino, primary, and Musto, Pellegrino, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 1 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters

Author

Negrini, Massimo, primary, Cutrona, Giovanna, primary, Bassi, Cristian, primary, Fabris, Sonia, primary, Zagatti, Barbara, primary, Colombo, Monica, primary, Ferracin, Manuela, primary, D'Abundo, Lucilla, primary, Saccenti, Elena, primary, Matis, Serena, primary, Lionetti, Marta, primary, Agnelli, Luca, primary, Gentile, Massimo, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, Reverberi, Daniele, primary, Rigolin, Gianmatteo, primary, Calin, George A., primary, Sabbioni, Silvia, primary, Russo, Giandomenico, primary, Tassone, Pierfrancesco, primary, Morabito, Fortunato, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia

Author

Bomben, Riccardo, primary, Rossi, Francesca Maria, primary, Vit, Filippo, primary, Bittolo, Tamara, primary, D'Agaro, Tiziana, primary, Zucchetto, Antonella, primary, Tissino, Erika, primary, Pozzo, Federico, primary, Vendramini, Elena, primary, Degan, Massimo, primary, Zaina, Eva, primary, Cattarossi, Ilaria, primary, Varaschin, Paola, primary, Nanni, Paola, primary, Berton, Michele, primary, Braida, Alessandra, primary, Polesel, Jerry, primary, Cohen, Jared A., primary, Santinelli, Enrico, primary, Biagi, Annalisa, primary, Gentile, Massimo, primary, Morabito, Fortunato, primary, Fronza, Gilberto, primary, Pozzato, Gabriele, primary, D'Arena, Giovanni, primary, Olivieri, Jacopo, primary, Bulian, Pietro, primary, Pepper, Chris, primary, Hockaday, Anna, primary, Schuh, Anna, primary, Hillmen, Peter, primary, Rossi, Davide, primary, Chiarenza, Annalisa, primary, Zaja, Francesco, primary, Di Raimondo, Francesco, primary, Del Poeta, Giovanni, primary, and Gattei, Valter, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

48. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

Author

Lionetti, Marta, primary, Musto, Pellegrino, primary, Di Martino, Maria Teresa, primary, Fabris, Sonia, primary, Agnelli, Luca, primary, Todoerti, Katia, primary, Tuana, Giacomo, primary, Mosca, Laura, primary, Gallo Cantafio, Maria E., primary, Grieco, Vitina, primary, Bianchino, Gabriella, primary, D'Auria, Fiorella, primary, Statuto, Teodora, primary, Mazzoccoli, Carmela, primary, De Luca, Luciana, primary, Petrucci, Maria Teresa, primary, Offidani, Massimo, primary, Di Raimondo, Francesco, primary, Falcone, Antonietta, primary, Caravita, Tommaso, primary, Omede', Paola, primary, Morabito, Fortunato, primary, Tassone, Pierfrancesco, primary, Boccadoro, Mario, primary, Palumbo, Antonio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 2 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters

Author

Negrini, Massimo, primary, Cutrona, Giovanna, primary, Bassi, Cristian, primary, Fabris, Sonia, primary, Zagatti, Barbara, primary, Colombo, Monica, primary, Ferracin, Manuela, primary, D'Abundo, Lucilla, primary, Saccenti, Elena, primary, Matis, Serena, primary, Lionetti, Marta, primary, Agnelli, Luca, primary, Gentile, Massimo, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, Reverberi, Daniele, primary, Rigolin, Gianmatteo, primary, Calin, George A., primary, Sabbioni, Silvia, primary, Russo, Giandomenico, primary, Tassone, Pierfrancesco, primary, Morabito, Fortunato, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results